AJANTPHARM - Ajanta Pharma Ltd. Share Price

Pharmaceuticals & Biotechnology

Sharesguru Stock Score

AJANTPHARM

52/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

₹2928.90-168.20(-5.43%)

Market Closed as of May 29, 2026, 15:30 IST

Select time range

Pros

Size: Market Cap wise it is among the top 20% companies of india.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Growth: Good revenue growth. With 44.7% growth over past three years, the company is going strong.

Balance Sheet: Strong Balance Sheet.

Profitability: Very strong Profitability. One year profit margin are 19%.

Technicals: Bullish SharesGuru indicator.

Smart Money: Smart money has been increasing their position in the stock.

Past Returns: Outperforming stock! In past three years, the stock has provided 33.7% return compared to 8.9% by NIFTY 50.

Valuation
Market Cap	38.58 kCr
Price/Earnings (Trailing)	36.53
Price/Sales (Trailing)	6.86
EV/EBITDA	24.69
Price/Free Cashflow	235.2
MarketCap/EBT	28
Enterprise Value	38.69 kCr

Fundamentals
Revenue (TTM)	5.62 kCr
Rev. Growth (Yr)	24.8%
Earnings (TTM)	1.06 kCr
Earnings Growth (Yr)	18.4%

Profitability
Operating Margin	24%
EBT Margin	24%
Return on Equity	23.33%
Return on Assets	17.16%
Free Cashflow Yield	0.43%

Growth & Returns
Price Change 1W	-4.9%
Price Change 1M	11.7%
Price Change 6M	22%
Price Change 1Y	19.1%
3Y Cumulative Return	33.7%
5Y Cumulative Return	18.4%
7Y Cumulative Return	23.8%
10Y Cumulative Return	11.7%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	-428.92 Cr
Cash Flow from Operations (TTM)	529.19 Cr
Cash Flow from Financing (TTM)	-167.92 Cr
Cash & Equivalents	103.26 Cr
Free Cash Flow (TTM)	164.03 Cr
Free Cash Flow/Share (TTM)	13.13

Balance Sheet
Total Assets	6.15 kCr
Total Liabilities	1.63 kCr
Shareholder Equity	4.53 kCr
Current Assets	3.74 kCr
Current Liabilities	1.42 kCr
Net PPE	1.73 kCr
Inventory	938.54 Cr
Goodwill	0.00

Capital Structure & Leverage
Debt Ratio	0.03
Debt/Equity	0.05
Interest Coverage	84.52
Interest/Cashflow Ops	33.85

Dividend & Shareholder Returns
Dividend/Share (TTM)	28
Dividend Yield	0.91%
Shares Dilution (1Y)	0.00%
Shares Dilution (3Y)	-2.5%

Technical Indicators
RSI (14d)	49.32
RSI (5d)	3.73
RSI (21d)	65.35
MACD Signal	Sell
Stochastic Oscillator Signal	Hold
SharesGuru Signal	Buy
RSI Signal	Hold
RSI5 Signal	Buy
RSI21 Signal	Hold
SMA 5 Signal	Sell
SMA 10 Signal	Sell
SMA 20 Signal	Buy
SMA 50 Signal	Buy
SMA 100 Signal	Buy

Shareholder Name	Holding %
Yogesh M Agrawal, trustee Yogesh Agrawal Trust	14.47%
Rajesh M Agrawal, trustee Rajesh Agrawal Trust	14.47%
Ravi P Agrawal, trustee Ravi Agrawal Trust	13%
Aayush M Agrawal, trustee Aayush Agrawal Trust	11.3%
Gabs Investments Pvt Ltd	10.08%
Uti-Flexi Cap Fund	3.19%
Ganga Exports being represented by Yogesh Agrawal, Rajesh Agrawal & Ravi Agrawal	2.68%
Tata Aia Life Insurance Co Ltd-Whole Life Mid Cap Equity Fund-Ulif 009 04/01/07 Wle 110	1.77%
Kotak Small Cap Fund	1.59%
Canara Robeco Mutual Fund A/C Canara Robeco Small Cap Fund	1.48%
Aditya Birla Sun Life Trustee Private Limited A/C Aditya Birla Sun Life Midcap Fund	1.1%
Ravi P Agrawal	0.23%
Aayush M Agrawal	0.02%
Mannalal B. Agrawal	0%

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical Industries	4.42 LCr	60.43 kCr	+13.60%	+9.80%	38.51	7.31	-	-
CIPLA	Cipla	1.13 LCr	29.04 kCr	+9.40%	-4.50%	29.13	3.89	-	-
DRREDDY	Dr. Reddy's Lab	1.11 LCr	35.06 kCr	+0.90%	+7.10%	26.38	3.16	-	-
LUPIN	Lupin	1.04 LCr	28.38 kCr	-1.30%	+14.00%	19.41	3.65	-	-
AUROPHARMA	Aurobindo Pharma	84.87 kCr	34.18 kCr	+3.40%	+23.70%	24.22	2.48	-	-

Description	(%) Q/Q	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Revenue From Operations	17.3%	5,453	4,648	4,209	3,743	3,341	2,890
Other Income	83.9%	172	94	85	99	116	26
Total Income	18.6%	5,625	4,743	4,293	3,841	3,457	2,916
Cost of Materials	8.3%	917	847	939	878	779	706
Purchases of stock-in-trade	-8%	230	250	166	146	136	90
Employee Expense	18.5%	1,291	1,090	900	785	646	548
Finance costs	-25%	16	21	7.21	5.84	10	8.27
Depreciation and Amortization	20.3%	173	144	135	131	125	116
Other expenses	28.9%	1,583	1,228	1,070	1,124	934	698
Total Expenses	19.5%	4,247	3,553	3,179	3,096	2,547	2,015
Profit Before exceptional items and Tax	15.9%	1,378	1,189	1,114	745	909	900
Exceptional items before tax	-	0	0	0	0	0	0
Total profit before tax	15.9%	1,378	1,189	1,114	745	909	900
Current tax	-3.9%	300	312	322	197	192	261
Deferred tax	147.2%	22	-43.53	-24.3	-39.97	5.13	-15.05
Total tax	19.8%	322	269	298	157	197	246
Total profit (loss) for period	14.8%	1,056	920	816	588	713	654
Other comp. income net of taxes	3194.1%	29	1.85	0.81	15	-7.97	-6.45
Total Comprehensive Income	17.7%	1,085	922	817	603	705	647
Earnings Per Share, Basic	15.1%	84.53	73.56	64.82	45.89	54.966667	50.06
Earnings Per Share, Diluted	15.1%	84.51	73.53	64.77	45.89	54.966667	50.06

Description	(%) Q/Q	Mar-2026	Dec-2025	Sep-2025	Jun-2025	Mar-2025	Dec-2024
Revenue From Operations	3.4%	1,422	1,375	1,354	1,303	1,170	1,146
Other Income	150%	61	25	59	26	18	30
Total Income	5.9%	1,483	1,400	1,413	1,329	1,189	1,177
Cost of Materials	9.4%	257	235	218	207	191	210
Purchases of stock-in-trade	32.1%	71	54	53	52	80	79
Employee Expense	3%	341	331	317	303	280	265
Finance costs	-66.8%	2.36	5.1	3.39	5.26	6.07	7.91
Depreciation and Amortization	2.3%	45	44	43	41	40	36
Other expenses	17.9%	443	376	392	373	310	302
Total Expenses	9.1%	1,136	1,041	1,072	998	919	869
Profit Before exceptional items and Tax	-3.4%	347	359	341	331	269	307
Total profit before tax	-3.4%	347	359	341	331	269	307
Current tax	-30.2%	61	87	78	74	62	95
Deferred tax	690.2%	19	-2.05	2.32	2.29	-17.81	-20.34
Total tax	-6%	80	85	81	76	44	75
Total profit (loss) for period	-2.6%	267	274	260	255	225	233
Other comp. income net of taxes	1025.8%	18	2.51	8.3	0.16	2.04	1.44
Total Comprehensive Income	3.3%	285	276	268	256	227	234
Earnings Per Share, Basic	-2.7%	21.35	21.91	20.83	20.44	18	18.6
Earnings Per Share, Diluted	-2.7%	21.34	21.91	20.82	20.43	18	18.59

Description	(%) Q/Q	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Revenue From Operations	12.1%	4,846	4,322	3,971	3,411	3,141	2,719
Other Income	70.6%	204	120	116	133	140	104
Total Income	13.7%	5,050	4,442	4,088	3,544	3,280	2,822
Cost of Materials	8.3%	917	847	939	878	773	704
Purchases of stock-in-trade	18.6%	218	184	162	149	116	101
Employee Expense	18.1%	1,194	1,011	834	720	586	498
Finance costs	-55.8%	2.59	4.6	6.8	5.23	9.12	6.9
Depreciation and Amortization	20.9%	169	140	132	127	121	111
Other expenses	25.9%	1,377	1,094	938	986	831	573
Total Expenses	17.1%	3,819	3,262	2,991	2,844	2,380	1,920
Profit Before exceptional items and Tax	4.3%	1,231	1,180	1,097	700	901	902
Exceptional items before tax	-	0	0	0	0	0	0
Total profit before tax	4.3%	1,231	1,180	1,097	700	901	902
Current tax	7.4%	277	258	278	144	171	217
Deferred tax	59.4%	7.6	5.14	12	-2.93	9.51	9.77
Total tax	8%	284	263	290	141	181	226
Total profit (loss) for period	3.3%	947	917	807	559	720	676
Other comp. income net of taxes	80.8%	-0.31	-5.83	-2.52	-2.27	0.36	-1.33
Total Comprehensive Income	4%	947	911	805	556	720	674
Earnings Per Share, Basic	3.5%	75.79	73.28	64.11	43.61	55.52	51.726667
Earnings Per Share, Diluted	3.5%	75.77	73.25	64.06	43.61	55.52	51.726667

Description	(%) Q/Q	Mar-2026	Dec-2025	Sep-2025	Jun-2025	Mar-2025	Dec-2024
Revenue From Operations	0.3%	1,211	1,207	1,220	1,209	1,014	1,102
Other Income	148%	63	26	75	41	18	33
Total Income	3.4%	1,274	1,232	1,295	1,249	1,032	1,135
Cost of Materials	9.4%	257	235	218	207	191	210
Purchases of stock-in-trade	0%	58	58	52	50	57	40
Employee Expense	2.3%	313	306	293	281	258	246
Finance costs	-300%	-0.74	1.87	0.73	0.73	0.67	2.48
Depreciation and Amortization	4.9%	44	42	42	40	39	35
Other expenses	29.3%	394	305	343	335	274	266
Total Expenses	11.7%	1,016	910	973	920	804	803
Profit Before exceptional items and Tax	-19.9%	258	322	322	329	228	332
Total profit before tax	-19.9%	258	322	322	329	228	332
Current tax	-8.3%	67	73	66	71	39	76
Deferred tax	-308.3%	-7	4.84	6.47	3.29	-4.38	3.32
Total tax	-22.4%	60	77	72	74	35	80
Total profit (loss) for period	-19.7%	197	245	250	255	193	252
Other comp. income net of taxes	258%	2.28	0.19	0.47	-3.25	-1.43	-0.41
Total Comprehensive Income	-18.4%	200	245	250	252	192	252
Earnings Per Share, Basic	-20.5%	15.79	19.61	19.98	20.41	15.46	20.16
Earnings Per Share, Diluted	-20.5%	15.79	19.61	19.97	20.4	15.45	20.15

Description	(%) Q/Q	Mar-2026	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023
Cash and cash equivalents	14.6%	103	90	175	64	129	262
Current investments	-34.1%	560	849	439	677	330	213
Loans, current	-37%	1.68	2.08	2.54	20	34	23
Total current financial assets	5.6%	2,529	2,395	1,803	1,794	1,761	1,646
Inventories	15.7%	939	812	904	846	828	786
Total current assets	10.1%	3,735	3,394	2,830	2,786	2,722	2,563
Property, plant and equipment	-0.8%	1,726	1,740	1,625	1,360	1,384	1,397
Capital work-in-progress	77.2%	258	146	176	349	256	205
Investment property	-	0	0	0	0	0	0
Non-current investments	12.5%	28	25	25	25	19	25
Total non-current financial assets	9.4%	36	33	34	34	28	36
Total non-current assets	6.1%	2,419	2,279	2,172	1,996	1,907	1,870
Total assets	8.5%	6,155	5,672	5,015	4,790	4,638	4,433
Borrowings, non-current	-	0	0	0	2.42	0	0
Total non-current financial liabilities	8.1%	41	38	36	374	25	24
Provisions, non-current	31.6%	51	39	80	88	40	23
Total non-current liabilities	7.1%	212	198	229	577	175	152
Borrowings, current	5%	212	202	2.59	0	1.49	0.91
Total current financial liabilities	18.8%	1,261	1,062	841	421	773	681
Provisions, current	31.8%	30	23	23	0	18	12
Current tax liabilities	-89.3%	5.49	43	41	55	45	82
Total current liabilities	22.1%	1,416	1,160	996	537	895	799
Total liabilities	20%	1,628	1,357	1,225	1,114	1,071	951
Equity share capital	0%	25	25	25	25	25	25
Total equity	4.9%	4,527	4,315	3,790	3,677	3,567	3,482
Total equity and liabilities	8.5%	6,155	5,672	5,015	4,790	4,638	4,433

Description	(%) Q/Q	Mar-2026	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023
Cash and cash equivalents	33.3%	89	67	49	27	62	200
Current investments	-34.1%	560	849	439	677	330	213
Loans, current	-37%	1.68	2.08	2.54	20	15	22
Total current financial assets	-3.3%	2,027	2,097	1,719	1,725	1,635	1,559
Inventories	26.3%	845	669	739	694	678	626
Current tax assets	-	0	0	0	0	0	0
Total current assets	6.1%	3,119	2,939	2,567	2,550	2,433	2,306
Property, plant and equipment	-0.8%	1,723	1,737	1,622	1,353	1,377	1,389
Capital work-in-progress	77.2%	258	146	176	349	256	205
Investment property	-	0	0	0	0	0	0
Non-current investments	7.1%	46	43	43	44	37	43
Total non-current financial assets	8.3%	53	49	51	52	46	54
Total non-current assets	6.5%	2,198	2,064	1,978	1,853	1,776	1,743
Total assets	6.3%	5,317	5,003	4,554	4,412	4,217	4,049
Total non-current financial liabilities	11.1%	31	28	25	22	24	24
Provisions, non-current	31.6%	51	39	80	67	40	23
Total non-current liabilities	7.5%	202	188	218	204	174	152
Total current financial liabilities	32%	736	558	532	502	514	447
Provisions, current	31.8%	30	23	23	21	18	12
Current tax liabilities	-87.9%	5.49	38	17	58	37	57
Total current liabilities	29.7%	891	687	711	678	629	541
Total liabilities	24.9%	1,093	875	929	882	804	693
Equity share capital	0%	25	25	25	25	25	25
Total equity	2.3%	4,224	4,128	3,625	3,530	3,414	3,356
Total equity and liabilities	6.3%	5,317	5,003	4,554	4,412	4,217	4,049

Description	(%) Q/Q	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Finance costs	-25%	16	21	7.21	5.84	10	-
Change in inventories	57.7%	-30.95	-74.51	-12.3	-22.37	-25.66	-
Depreciation	20.3%	173	144	135	131	125	-
Impairment loss / reversal	932.4%	4.08	0.63	-3.49	5.37	7.85	-
Unrealised forex losses/gains	-422.9%	-58.14	-10.31	-9.42	-14.08	-21.19	-
Adjustments for interest income	1.7%	60	59	38	18	4.08	-
Share-based payments	-81.6%	1.53	3.88	5.49	0.22	0.3	-
Net Cashflows from Operations	-40%	888	1,480	1,097	943	801	-
Income taxes paid (refund)	11.2%	359	323	312	151	239	-
Other inflows (outflows) of cash	-	0	0	0	0	0.01	-
Net Cashflows From Operating Activities	-54.3%	529	1,157	785	792	562	-
Cash payment for investment in partnership firm or association of persons or LLP	-57%	3.26	6.25	0	0	25	-
Proceeds from sales of PPE	3050%	5.41	1.14	13	0.73	18	-
Purchase of property, plant and equipment	14.8%	365	318	152	174	149	-
Interest received	2.3%	45	44	27	0.52	0.9	-
Other inflows (outflows) of cash	-65.5%	-0.39	0.16	-0.21	4.35	27	-
Net Cashflows From Investing Activities	-13.9%	-428.92	-376.52	65	-559.6	-74.1	-
Proceeds from issuing other equity instruments	-1%	0	0.01	0	0	0	-
Payments to acquire or redeem entity's shares	-100.3%	0	353	389	1.44	354	-
Proceeds from borrowings	207900%	209	1.1	0.06	0	0.23	-
Repayments of borrowings	-	0	0	0	0.49	0	-
Payments of lease liabilities	0%	15	15	16	14	17	-
Dividends paid	0.3%	350	349	642	90	82	-
Interest paid	-25%	13	17	3.53	2.33	7.35	-
Other inflows (outflows) of cash	-	0	0	0	0.33	0	-
Net Cashflows from Financing Activities	77%	-167.92	-733.41	-1,051.06	-107.87	-460.04	-
Effect of exchange rate on cash eq.	-95.1%	-4.21	-1.67	0.26	-0.84	0.95	-
Net change in cash and cash eq.	-261.9%	-71.86	46	-200.34	123	29	-

Description	(%) Q/Q	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Finance costs	-55.8%	2.59	4.6	6.8	5.23	9.12	-
Change in inventories	-70.3%	-105.42	-61.5	5.98	-48.67	-0.89	-
Depreciation	20.9%	169	140	132	127	121	-
Impairment loss / reversal	845.9%	3.76	0.63	0	-0.84	7.56	-
Unrealised forex losses/gains	-422.9%	-58.14	-10.31	-9.42	-14.08	-21.19	-
Dividend income	71.4%	37	22	29	35	22	-
Adjustments for interest income	1.7%	60	59	38	25	12	-
Share-based payments	-82.3%	1.53	4	4.87	0.22	0.3	-
Net Cashflows from Operations	-17.9%	1,097	1,336	988	862	736	-
Income taxes paid (refund)	3.9%	293	282	252	126	193	-
Other inflows (outflows) of cash	-	0	0	0	0	0.02	-
Net Cashflows From Operating Activities	-23.7%	804	1,054	735	736	542	-
Cash payment for investment in partnership firm or association of persons or LLP	-57%	3.26	6.25	0	0	25	-
Proceeds from sales of PPE	-233.3%	0.5	0.85	12	0.57	18	-
Purchase of property, plant and equipment	15.8%	367	317	153	176	147	-
Dividends received	71.4%	37	22	29	35	22	-
Interest received	-8.3%	45	49	38	25	12	-
Other inflows (outflows) of cash	0.9%	-0.12	-0.13	0.44	4.35	27	-
Net Cashflows From Investing Activities	-14.2%	-399.55	-349.6	105	-501.31	-66.04	-
Proceeds from issuing shares	-1%	0	0.01	0	0	0	-
Payments to acquire or redeem entity's shares	-100.3%	0	353	389	1.44	354	-
Payments of lease liabilities	-21.5%	9.63	12	13	12	14	-
Dividends paid	0.3%	350	349	642	90	82	-
Interest paid	-278%	0.27	1.41	3.42	1.76	6.52	-
Net Cashflows from Financing Activities	49.7%	-359.62	-715.71	-1,047.7	-105.12	-457.32	-
Effect of exchange rate on cash eq.	-95.1%	-4.21	-1.67	0.26	-0.84	0.95	-
Net change in cash and cash eq.	375%	40	-13.18	-207.07	129	20	-

AJANTPHARM - Ajanta Pharma Ltd. Share Price

AJANTPHARM

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

AJANTPHARM

AJANTPHARM - Ajanta Pharma Ltd. Share Price

AJANTPHARM

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

AJANTPHARM

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Ajanta Pharma Ltd. do?

Important Disclosure & Data Context

Valuation

Fundamentals

Profitability

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Ajanta Pharma Ltd. do?

Important Disclosure & Data Context